Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04394650 · ClinicalTrials.gov registry record · Phase 1
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT04394650 is a Phase 1 study that has completed, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 78 participants.
The verdict
NCT04394650, a Phase 1 study, has completed, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in participants with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CC-98633 to establish a recommended Phase 2 dose RP2D(s); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D(s).
Interventions
- BIOLOGICAL CC-98633
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2024-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04394650
The ClinicalTrials.gov registry entry for NCT04394650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juno Therapeutics, a Subsidiary of Celgene, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-98633 is the first listed.
NCT04394650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04394650 about?
NCT04394650 is a clinical study titled "A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma". This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in participants with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation p...
What is the current status of trial NCT04394650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2020-08-18. Estimated completion is 2024-07-03.
What interventions are being tested in trial NCT04394650?
The interventions under investigation include: CC-98633 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04394650?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.